Khodr Tello, Athiththan Yogeswaran, Raphael W Majeed, David G Kiely, Allan Lawrie, Evan Brittain, Jeffrey S Annis, Horst Olschewski, Gabor Kovacs, Paul M Hassoun, Aparna Balasubramanian, Ziad Konswa, Andrew J Sweatt, Roham T Zamanian, Martin R Wilkins, Luke Howard, Alexandra Arvanitaki, George Giannakoulas, Hector R Cajigas, Robert Frantz, Paul G Williams, Marlize Frauendorf, Kurt Marquardt, Tobiah Antoine, Meike Fuenderich, Manuel Richter, Friedrich Grimminger, Hossein-Ardeschir Ghofrani, Jochen Wilhelm, Werner Seeger
BACKGROUND: Patients with COPD frequently develop pulmonary hypertension (PH-COPD). Severe PH-COPD, identified by a pulmonary vascular resistance (PVR) >5 Wood Units (WU), is closely linked to impaired transplant-free survival. The impact of PH-targeting pharmacotherapy in this context remains unclear. RESEARCH QUESTION: Is PH-targeted therapy associated with improved transplant-free survival in PH-COPD? STUDY DESIGN AND METHODS: This study included PVRI GoDeep meta-registry patients with PH-COPD and available right heart catheterization at diagnosis...
August 23, 2024: Chest